Internap Corporation (NASDAQ:INAP) shares remains unchanged in last trading session and ended the day at $7.18. INAP Gross Margin is 45.60% and its has a return on assets of -7.90%. Internap Corporation (NASDAQ:INAP) quarterly performance is -13.18%.
On 5 November, Internap Corporation (NASDAQ:INAP) announced financial results for the third quarter of 2015. Revenue totaled $78.3 million in the third quarter, a decrease of 7% year-over-year and 3% sequentially.
Eastman Chemical Co. (NYSE:EMN) ended the last trading day at $70.90. Company weekly volatility is calculated as 2.43% and price to cash ratio as 34.10. Eastman Chemical Co. (NYSE:EMN) showed a weekly performance of 5.16%.
Jefferies Group restated their buy rating on shares of Eastman Chemical Co. (NYSE:EMN) in a research note issued to investors on Thursday morning, MarketBeat.com reports. The brokerage currently has a $90.00 target price on the stock.
Alphabet Inc (NASDAQ:GOOG) caters to the Technology space. Its weekly performance is 0.98%. On the last day of trading company shares ended up at $738.41. Alphabet Inc (NASDAQ:GOOG) distance from 50-day simple moving average (SMA50) is -14.92%.
Alphabet Inc (NASDAQ:GOOG) said it tapped enterprise-technology veteran Diane Greene to run its cloud-computing businesses, including Google for Work, Cloud Platform and Google Apps. Greene co-founded VMware Inc , a pioneer of technology that lets companies handle big computing tasks across many computers in their data centers.
Curis, Inc. (NASDAQ:CRIS) shares decreased -0.80% in last trading session and ended the day at $2.48. CRIS Gross Margin is 94.90% and its has a return on assets of -51.20%. Curis, Inc. (NASDAQ:CRIS) quarterly performance is -3.50%.
On 8 November, Curis, Inc. (NASDAQ:CRIS) announced that its collaborator Aurigene presented preclinical data from two programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics including: (1) CA-170 (previously AUPM-170), a first-in-class oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA), and (2) the interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor program.
JD.com, Inc. (NASDAQ:JD) ended the last trading day at $29.05. Company weekly volatility is calculated as 5.95% and price to cash ratio as 10.66. JD.com, Inc. (NASDAQ:JD) showed a weekly performance of 0.94%.
On 16 November, JD.com, Inc. (NASDAQ:JD) said third-quarter revenues rose 52 percent from a year ago, in line with expectations on Monday, as user numbers and orders grew at a rapid clip.
Leave a Reply